CCEL Form 4: Director receives 5,300 stock options at $4.35

Rhea-AI Filing Summary

Cryo-Cell International (CCEL) director reported a new stock option grant. On 10/21/2025, the director received options for 5,300 shares at an exercise price of $4.35, exercisable on 10/21/2025 and expiring on 10/21/2035. Following the reported transactions, the director directly beneficially owned 57,901 shares of common stock. The filing also lists multiple prior stock option awards with various exercise prices and maturities.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berger Harold D.

(Last) (First) (Middle)

700 BROOKER CREEK BLVD

SUITE 1800

(Street)

OLDSMAR FL 34677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRYO CELL INTERNATIONAL INC [ CCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								57,901	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.53							08/30/2019	08/30/2029	Common Stock	7,500		7,500	D
Stock Option	$7.74							11/25/2019	11/25/2029	Common Stock	5,300		5,300	D
Stock Option	$7.85							09/22/2020	09/22/2030	Common Stock	5,300		5,300	D
Stock Option	$12.63							10/20/2021	10/20/2031	Common Stock	5,300		5,300	D
Stock Option	$6.5							10/03/2022	10/03/2032	Common Stock	5,300		5,300	D
Stock Option	$4.9							10/10/2023	10/10/2033	Common Stock	5,300		5,300	D
Stock Option	$5.82							10/29/2024	10/29/2034	Common Stock	5,300		5,300	D
Stock Option	$4.35	10/21/2025		A		5,300		10/21/2025	10/21/2035	Common Stock	5,300	$4.35	5,300	D

Explanation of Responses:

	/s/ Harold Berger	10/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CCEL disclose in this Form 4?

A director received a stock option grant for 5,300 shares at an exercise price of $4.35 on 10/21/2025.

What is the exercise price and term of the new CCEL options?

The options have an exercise price of $4.35, are exercisable on 10/21/2025, and expire on 10/21/2035.

How many CCEL common shares does the director own after the transactions?

The director beneficially owned 57,901 common shares directly after the reported transactions.

What is the size of the new CCEL option grant?

The new grant covers 5,300 shares of CCEL common stock.

Who filed the CCEL Form 4?

A director of Cryo-Cell International filed the Form 4, as indicated by the checked relationship box and signature line.

Does the filing list other option awards?

Yes. The filing includes several prior stock option awards with different exercise prices and expiration dates.